...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >Long Noncoding RNA LINC01134 Promotes Hepatocellular Carcinoma Metastasis via Activating AKT1S1 and NF-κB Signaling
【24h】

Long Noncoding RNA LINC01134 Promotes Hepatocellular Carcinoma Metastasis via Activating AKT1S1 and NF-κB Signaling

机译:长度非编码RNA LINC01134通过激活AKT1S1和NF-κB信号促进肝细胞癌转移

获取原文

摘要

Hepatocellular carcinoma is one of the most common malignancies with poor outcomes. The main cause of HCC-related deaths are recurrence and metastasis. Long noncoding RNAs (lncRNAs) are recently identified as critical regulators in cancers. However, the lncRNAs involved in HCC recurrence and metastasis are poorly understand. In this study, via analyzing the Cancer Genome Atlas (TCGA) Liver Hepatocellular Carcinoma (LIHC) dataset, we identified a novel lncRNA LINC01134, which is highly expressed in HCC tissues and correlated with microvascular invasion, macrovascular invasion, recurrence, and poor overall survival of HCC patients. Functional experiments revealed that ectopic expression of LINC01134 promotes HCC cell migration and invasion in vitro, and HCC liver metastasis and lung metastasis in vivo. Knockdown of LINC01134 represses HCC cell migration and invasion in vitro, and HCC liver metastasis and lung metastasis in vivo. Mechanistically, we found that LINC01134 directly binds the promoter of AKT1S1 and activates AKT1S1 expression. Via activating AKT1S1, LINC01134 further activates NF-κB signaling. The expression of LINC01134 is significantly positively correlated with that of AKT1S1 in HCC tissues. In line with LINC01134, AKT1S1 is also highly expressed in HCC tissues and correlated with poor survival of HCC patients. Functional rescue experiments showed that repressing AKT1S1 or NF-κB signaling both abrogate the roles of LINC01134 in HCC. Taken together, these findings recognized LINC01134 as a novel oncogenic lncRNA, which indicates vascular invasion, recurrence, and poor overall survival of HCC patients. LINC01134 promotes HCC metastasis via activating AKT1S1 expression and subsequently activating NF-κB signaling. This study suggested LINC01134 as a potential prognostic biomarker and therapeutic target for HCC.
机译:肝细胞癌是最常见的恶性癌症之一。 HCC相关死亡的主要原因是复发和转移。最近鉴定为癌症中的临界调节剂的长量rNA(LNCRNA)。然而,涉及HCC复发和转移的LNCRNA也不明白。在本研究中,通过分析癌症基因组地图集(​​TCGA)肝肝细胞癌(LIHC)数据集,我们鉴定了一种新的LNCRNA LINC01134,其在HCC组织中高度表达并与微血管侵袭,大血管侵袭,复发和贫困的整体生存相关HCC患者。功能实验表明,LINC01134的异位表达促进了体外体外HCC细胞迁移和侵袭,以及体内HCC肝转移和肺转移。 LINC01134的敲低抑制了体外体外的HCC细胞迁移和侵袭和HCC肝转移和肺转移。机械地,我们发现LINC01134直接结合AKT1S1的启动子并激活AKT1S1表达。通过激活AKT1S1,LINC01134进一步激活NF-κB信号传导。 LINC01134的表达与HCC组织中的AKT1S1显着呈正相关。符合LINC01134,AKT1S1在HCC组织中也高度表达,并与HCC患者的差的存活率相关。功能救援实验表明,抑制AKT1S1或NF-κB信号传导,既消除了LINC01134在HCC中的角色。总之,这些发现将LINC01134认识为一种新型致癌LNCRNA,表明血管侵袭,复发和HCC患者的整体存活差。 LINC01134通过激活AKT1S1表达和随后激活NF-κB信号传导来促进HCC转移。该研究表明LINC01134作为HCC的潜在预后生物标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号